{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:55:12Z","timestamp":1792522512740,"version":"4.5.0"},"reference-count":21,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6_Suppl","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,3]]},"DOI":"10.4269\/ajtmh.14-0586","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T02:11:17Z","timestamp":1429582277000},"page":"31-38","source":"Crossref","is-referenced-by-count":9,"title":["Chemical and Bioassay Techniques to Authenticate Quality of the Anti-Leishmanial Drug Miltefosine"],"prefix":"10.4269","volume":"92","author":[{"given":"Harparkash","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey E.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Coumbarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence. WHO Leishmaniasis Control Team","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"R2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2013challenges and opportunities","volume":"17","author":"Croft","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"R4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"R5","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-3156.2007.01974.x","article-title":"Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal\u2013the challenges for diagnosis and treatment","volume":"13","author":"Sundar","year":"2008","journal-title":"Trop Med Int Health"},{"key":"R7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S1473-3099(08)70241-X","article-title":"Global health-care implications of substandard medicines","volume":"8","author":"Senior","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1039\/c2an15641e","article-title":"Characterization and identification of suspected counterfeit miltefosine capsules","volume":"137","author":"Dorlo","year":"2012","journal-title":"Analyst (Lond)"},{"key":"R9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jchromb.2008.02.005","article-title":"Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry","volume":"865","author":"Dorlo","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R10","doi-asserted-by":"crossref","first-page":"e1544","DOI":"10.1371\/journal.pntd.0001544","article-title":"A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal","volume":"6","author":"Dorlo","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"R11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jac\/dkp500","article-title":"In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent","volume":"65","author":"Seifert","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R12","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials: new perspectives for old drugs","volume":"14","author":"Frezard","year":"2009","journal-title":"Molecules"},{"key":"R13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jinorgbio.2007.10.010","article-title":"New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate","volume":"102","author":"Fr\u00e9zard","year":"2008","journal-title":"J Inorg Biochem"},{"key":"R14","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/ijerph7124267","article-title":"Antimony toxicity","volume":"7","author":"Sundar","year":"2010","journal-title":"Int J Environ Res Public Health"},{"key":"R15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1590\/S0037-86821985000300011","article-title":"Pentavalent antimonials: old drugs for old diseases","volume":"18","author":"Marsden","year":"1985","journal-title":"Rev Soc Brasil Med Trop"},{"key":"R16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4269\/ajtmh.1998.59.139","article-title":"A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate","volume":"59","author":"Sundar","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"R17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1590\/S0037-86821996000500009","article-title":"Physico-chemical characteristics of meglumine antimoniate in different conditions","volume":"29","author":"Romero","year":"1996","journal-title":"Rev Soc Bras Med Trop"},{"key":"R18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4269\/ajtmh.1995.52.435","article-title":"Antimony oxidation states in antileishmanial drugs","volume":"52","author":"Franco","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"R19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1365-3156.2008.02106.x","article-title":"Substandard medicines in resource-poor settings: a problem that can no longer be ignored","volume":"13","author":"Caudron","year":"2008","journal-title":"Trop Med Int Health"},{"key":"R20","article-title":"Control of the Leishmaniases","year":"2010"},{"key":"R21","doi-asserted-by":"crossref","first-page":"e3020","DOI":"10.1371\/journal.pntd.0003020","article-title":"How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data","volume":"8","author":"Chowdhury","year":"2014","journal-title":"PLoS Negl Trop Dis"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T17:04:34Z","timestamp":1611767074000},"score":1,"resource":{"primary":{"URL":"https:\/\/ajtmh.org\/doi\/10.4269\/ajtmh.14-0586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,3]]},"references-count":21,"journal-issue":{"issue":"6_Suppl","published-print":{"date-parts":[[2015,6,3]]}},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.14-0586","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,3]]}}}